In-Pharmatechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals.
Mylan has announced that it has appointed two new members to its Board of Directors.
Melina Higgins, will join the Board with plenty of experience having been a former partner at Goldman Sachs & Co. and has served as Director for a number of companies in various industries.
U.S. Banker ranked Higgins as one of the Top 20 Nonbank Women in Finance.
Rajiv Malik, is the second appointment to Mylan’s Board of Directors.
Currently the company’s President, Malik has been at Mylan since 2007 serving in a variety of high-level roles.
Robert J. Coury, Executive Chairman of Mylan, said: "With these appointments, I am very pleased to continue to deliver on our objective of enhancing and strengthening Mylan at all levels, including its board of directors, as we seek to continue our exciting growth trajectory.”
Solasia Pharma is changing its management team and has promoted Yoshirai Arai (left) to position of President and Representative Director of the company.
Present CEO, Steve Engen (right), has also announced he is resigning in order to pursue a new career opportunity.
Arai spent 14 years at Amgen before arriving at Solasia in 2007.
Arai said: “I look forward to taking on this important role and responsibility in order to continue to build Solasia. We will accelerate our clinical programs in Asia, and will establish a new sales & marketing organization for commercialization of our 1st product in China. In addition, we will seek new compounds to strengthen our pipeline.”
Speciality pharmaceutical company Prosonix has announced the appointment of Cécile Miles as Chief Business Officer in order to help develop and drive Prosonix’ business development and commercial strategy.
David Hipkiss, CEO of Prosonix expressed his pleasure that Miles – who comes from being European Commercial Director at The Watson Group – was joining the company, adding:
“She will play a key role in driving Prosonix’ business development strategy over the coming years as we explore opportunities to capture the full potential value of our portfolio of directly substitutable inhaled generics and novel combination respiratory candidates.”
Dr. Tom Reynolds has been appointed on to the Board of Directors at MEI Pharma.
Reynolds has recently retired from his role of Chief Medical Officer at Seattle Genetics which he held from 2007. Prior to that he served as Vice-President at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010).
"His appointment is particularly timely as we prepare for the expansion of our clinical development program for Pracinostat in the months ahead," said Daniel P. Gold, President and CEO of MEI Pharma.
Ironwood Pharmaceuticals has appointed Dr. Mark Currie to senior vice president, chief scientific officer (CSO), and president of research and development (R&D).
Dr. Currie has been at Ironwood since 2002, leading the company’s R&D efforts.
Ironwood CEO Peter Hecht said that “Mark’s outstanding contributions to Ironwood are invaluable as we move our R&D efforts forward, growing our active pipeline and expanding our development efforts globally on behalf of our shareholders and the patients we aim to serve.”
Jane Henderson has been appointed Senior Vice President & Chief Business Officer at Kolltan Pharmaceuticals.
She comes with over 24 years of experience in life sciences finance, most recently serving as Vice President, Business Development at ISTA Pharmaceuticals.
“Jane is an important addition to the Kolltan senior team, bringing extensive deal-making and business development experience in the healthcare sector,” said Dr. Gerald McMahon, Kolltan’s President and CEO.